# US 2019/0169308 A1 · Novel bispecific polypeptides against cd137

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169308 A1
- Document ID: US20190169308A1
- Status: Published application
- Kind: A1
- Application number: 16/094,127
- Filed: 2017-04-24
- Published: 2019-06-06
- Earliest claimed: 2016-04-22
- Applicants: Alligator Bioscience AB
- Inventors: Eva Dahlén; Peter Ellmark; Christina Furebring; Per Norlén; Anna Säll; Laura von Schantz; Niina Veitonmäki; Laura Varas; Jessica Petersson; Sara Fritzell
- Web page: https://patentgrep.com/patent/US20190169308A1

## CPC

- C07K 16/30: from tumour cells
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides bispecific polypeptides comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen. Also provided are pharmaceutical compositions of such bispecific polypeptides and uses of the same in medicine.

## Claims

### Claim 1

A bispecific polypeptide comprising a first binding domain, designated B1, which is capable of binding specifically to CD137, and a second binding domain, designated B2, which is capable of specifically binding to a tumour cell-associated antigen.

### Claim 2 (depends on 1)

A polypeptide according to claim 1, wherein the first and/or second binding domains are/is selected from the group consisting of antibodies and antigen-binding fragments thereof.

### Claim 3 (depends on 2)

A polypeptide according to claim 2 wherein the antigen-binding fragment is selected from the group consisting of: Fv fragments (such as a single chain Fv fragment, or a disulphide-bonded Fv fragment), Fab-like fragments (such as a Fab fragment; a Fab′ fragment or a F(ab)2 fragment) and domain antibodies.

### Claim 4

A polypeptide according to any one of the preceding claims wherein the polypeptide is a bispecific antibody.

### Claim 5 (depends on 4)

A polypeptide according to claim 4 wherein:
(a) binding domain B1 and/or binding domain B2 is an intact IgG antibody;
(b) binding domain B1 and/or binding domain B2 is an Fv fragment;
(c) binding domain B1 and/or binding domain B2 is a Fab fragment; and/or
(d) binding domain B1 and/or binding domain B2 is a single domain antibody.

### Claim 6 (depends on 4, 5)

A polypeptide according to claim 4 or 5 wherein the bispecific antibody comprises a human Fc region or a variant of a said region, where the region is an IgG1, IgG2, IgG3 or IgG4 region, preferably an IgG1 or IgG4 Fc region.

### Claim 7 (depends on 6)

A polypeptide according to claim 6 wherein the Fc exhibits no or very low affinity for FcgR.

### Claim 8 (depends on 6, 7)

A polypeptide according to claim 6 or 7 wherein the Fc region is a variant of a human IgG1 Fc region comprising a mutation at one or more of the following positions:
L234, L235, P239, D265, N297 and/or P329.

### Claim 9 (depends on 8)

A polypeptide according to claim 8 wherein alanine is present at the mutated positions(s).

### Claim 10 (depends on 9)

A polypeptide according to claim 9 wherein the Fc region is a variant of a human IgG1 Fc region comprising the double mutations L234A and L235A.

### Claim 11 (depends on 4, 5, 6, 7, 8, 9, 10)

A polypeptide according to any one of claims 4 to 10 wherein the bispecific antibody is selected from the groups consisting of:
(a) bivalent bispecific antibodies, such as IgG-scFv bispecific antibodies (for example, wherein B1 is an intact IgG and B2 is an scFv attached to B1 at the N-terminus of a light chain and/or at the C-terminus of a light chain and/or at the N-terminus of a heavy chain and/or at the C-terminus of a heavy chain of the IgG, or vice versa);
(b) monovalent bispecific antibodies, such as a DuoBody® or a ‘knob-in-hole’ bispecific antibody (for example, an scFv-KIH, scFv-KIHr, a BiTE-KIH or a BiTE-KIHr;
(c) scFv2-Fc bispecific antibodies (for example, ADAPTIR™ bispecific antibodies);
(d) BITE/scFv2 bispecific antibodies;
(e) DVD-Ig bispecific antibodies or other IgG-FAb, FAb-IgG bispecific antibodies regardless of bivalency or linkers/connectors employed;
(f) DART-based bispecific antibodies (for example, DART2-Fc, DART2-Fc or DART);
(g) DNL-Fabs bispecific antibodies; and
(h) scFv-HSA-scFv bispecific antibodies.

### Claim 12 (depends on 11)

A polypeptide according to claim 11 wherein the bispecific antibody is an IgG-scFv bispecific antibody.

### Claim 13

A polypeptide according to any one of the preceding claims wherein binding domain B1 and binding domain B2 are fused directly to each other.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A polypeptide according to any one of claims 1 to 12 wherein binding domain B1 and binding domain B2 are joined via a polypeptide linker.

### Claim 15 (depends on 14)

A polypeptide according to claim 14 wherein the linker is selected from the group consisting of the amino acid sequence SGGGGSGGGGS (SEQ ID NO: 87), SGGGGSGGGGSAP (SEQ ID NO: 88), NFSQP (SEQ ID NO: 89), KRTVA (SEQ ID NO: 90), GGGSGGGG (SEQ ID NO: 91), GGGGSGGGGS (SEQ ID NO: 92), GGGGSGGGGSGGGGS (SEQ ID NO: 93), THTCPPCPEPKSSDK (SEQ ID NO:
140), GGGS (SEQ ID NO: 141), EAAKEAAKGGGGS (SEQ ID NO: 142), EAAKEAAK (SEQ ID NO: 143), or (SG)m, where m=1 to 7.

### Claim 16

A polypeptide according to any of the preceding claims, wherein the polypeptide is incapable of inducing antibody dependent cell cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and/or complement-dependent cytotoxicity (CDC).

### Claim 17

A polypeptide according to any of the preceding claims, wherein the polypeptide is capable of inducing tumour immunity.

### Claim 18

A polypeptide according to any one of the preceding claims, wherein the polypeptide is capable of inducing:
(a) activation of cytotoxic T cells, i.e. CD8+ T cells;
(b) activation of helper T cells, i.e. CD4+ T cells;
(c) activation of dendritic cells; and/or
(d) activation of natural killer cells; and/or
(e) reprograming of Tregs into effector T cells.

### Claim 19

A polypeptide according to any of the preceding claims wherein binding domain B1 binds to human CD137 with a KD of less than 10×10−9M, for example less than 4×10−9M or less than 1.2×10−9M.

### Claim 20

A polypeptide according to any of the preceding claims wherein binding domain B1 comprises:
(a) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1200/1201 (SEQ ID NOs: 54, 55 and 79 and/or SEQ ID NOs: 46, 65 and 72);
(b) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1202/1203 (SEQ ID NOs: 54, 55 and 80 and/or SEQ ID NOs: 60, 66 and 73);
(c) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1204/1205 (SEQ ID NOs: 54, 55 and 81 and/or SEQ ID NOs: 61, 67, 74);
(d) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1214/1215 (SEQ ID NOs: 54, 55 and 82 and/or SEQ ID NOs: 46, 68 and 75);
(e) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1618/1619 (SEQ ID NOs: 54, 55 and 83 and/or SEQ ID NOs: 62, 69 and 76);
(f) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1620/1621 (SEQ ID NOs: 54, 55 and 84 and/or SEQ ID NOs: 63, 70, and 77);
(g) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1626/1627 (SEQ ID NOs: 54, 55 and 85 and/or SEQ ID NOs: 64, 71 and 78);
(h) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3012/3013 (SEQ ID NOs: 156, 69 and 76 and/or SEQ ID NOs: 158, 155 and 83);
(i) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3014/3015 (SEQ ID NOs: 62, 69 and 76 and/or SEQ ID NOs: 159, 160 and 83);
(j) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3016/3017 (SEQ ID NOs: 62, 69 and 76 and/or SEQ ID NOs: 159, 155 and 83);
(k) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3018/3019 (SEQ ID NOs: 156, 69 and 76 and/or SEQ ID NOs: 158, 161 and 83);
(l) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3020/3021 (SEQ ID NOs: 156, 69 and 76 and/or SEQ ID NOs: 162, 163 and 83);
(m) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3022/3023 (SEQ ID NOs: 156, 69 and 76 and/or SEQ ID NOs: 159, 155 and 83);
(n) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3024/3025 (SEQ ID NOs: 156, 69 and 76 and/or SEQ ID NOs: 54, 55 and 83);
(o) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3026/3027 (SEQ ID NOs: 156, 69 and 76 and/or SEQ ID NOs: 162, 165 and 83);
(p) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3028/3029 (SEQ ID NOs: 157, 69 and 76 and/or SEQ ID NOs: 159, 166 and 83);
(q) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3030/3031 (SEQ ID NOs: 156, 69 and 76 and/or SEQ ID NOs: 54, 166 and 83);
(r) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3032/3033 (SEQ ID NOs: 156, 69 and 76 and/or SEQ ID NOs: 54, 55 and 83);
(s) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3034/3035 (SEQ ID NOs: 62, 69 and 76 and/or SEQ ID NOs: 54, 155 and 83); or
(t) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3036/3037 (SEQ ID NOs: 156, 69 and 76 and/or SEQ ID NOs: 162, 155 and 83).

### Claim 21

A polypeptide according to any of the preceding claims wherein binding domain B1 comprises:
(a) the heavy chain variable region and/or the light chain variable region of antibody 1200/1201 (SEQ ID NO: 19 and/or SEQ ID NO: 17);
(b) the heavy chain variable region and/or the light chain variable region of antibody 1202/1203 (SEQ ID NO: 23 and/or SEQ ID NO: 21);
(c) the heavy chain variable region and/or the light chain variable region of antibody 1204/1205 (SEQ ID NO: 25 and/or SEQ ID NO: 27);
(d) the heavy chain variable region and/or the light chain variable region of antibody 1214/1215 (SEQ ID NO: 31 and/or SEQ ID NO: 29);
(e) the heavy chain variable region and/or the light chain variable region of antibody 1618/1619 (SEQ ID NO: 35 and/or SEQ ID NO: 33);
(f) the heavy chain variable region and/or the light chain variable region of antibody 1620/1621 (SEQ ID NO: 39 and/or SEQ ID NO: 37);
(g) the heavy chain variable region and/or the light chain variable region of antibody 1626/1627 (SEQ ID NO: 43 and/or SEQ ID NO: 41);
(h) the heavy chain variable region and/or the light chain variable region of antibody 3012/3013 (SEQ ID NO: 114 and/or SEQ ID NO: 115);
(i) the heavy chain variable region and/or the light chain variable region of antibody 3014/3015 (SEQ ID NO: 116 and/or SEQ ID NO: 117);
(j) the heavy chain variable region and/or the light chain variable region of antibody 3016/3017 (SEQ ID NO: 118 and/or SEQ ID NO: 119);
(k) the heavy chain variable region and/or the light chain variable region of antibody 3018/3019 (SEQ ID NO: 120 and/or SEQ ID NO: 121);
(l) the heavy chain variable region and/or the light chain variable region of antibody 3020/3021 (SEQ ID NO: 122 and/or SEQ ID NO: 123);
(m)the heavy chain variable region and/or the light chain variable region of antibody 3022/3023 (SEQ ID NO: 124 and/or SEQ ID NO: 125);
(n) the heavy chain variable region and/or the light chain variable region of antibody 3024/3025 (SEQ ID NO: 126 and/or SEQ ID NO: 127);
(o) the heavy chain variable region and/or the light chain variable region of antibody 3026/3027 (SEQ ID NO: 128 and/or SEQ ID NO: 129);
(p) the heavy chain variable region and/or the light chain variable region of antibody 3028/3029 (SEQ ID NO: 130 and/or SEQ ID NO: 131);
(q) the heavy chain variable region and/or the light chain variable region of antibody 3030/3031 (SEQ ID NO: 132 and/or SEQ ID NO: 133);
(r) the heavy chain variable region and/or the light chain variable region of antibody 3032/3033 (SEQ ID NO: 134 and/or SEQ ID NO: 135);
(s) the heavy chain variable region and/or the light chain variable region of antibody 3034/3035 (SEQ ID NO: 136 and/or SEQ ID NO: 137); or
(t) the heavy chain variable region and/or the light chain variable region of antibody 3036/3037 (SEQ ID NO: 138 and/or SEQ ID NO: 139).

### Claim 22

A polypeptide according to any of the preceding claims wherein binding domain B1 comprises:
(a) the heavy chain and/or the light chain of antibody 1200/1201;
(b) the heavy chain and/or the light chain of antibody 1202/1203;
(c) the heavy chain and/or the light chain of antibody 1204/1205;
(d) the heavy chain and/or the light chain of antibody 1214/1215;
(e) the heavy chain and/or the light chain of antibody 1618/1619;
(f) the heavy chain and/or the light chain of antibody 1620/1621;
(g) the heavy chain and/or the light chain of antibody 1626/1627;
(h) the heavy chain and/or the light chain of antibody 3012/3013;
(i) the heavy chain and/or the light chain of antibody 3014/3015;
(j) the heavy chain and/or the light chain of antibody 3016/3017;
(k) the heavy chain and/or the light chain of antibody 3018/3019;
(l) the heavy chain and/or the light chain of antibody 3020/3021;
(m)the heavy chain and/or the light chain of antibody 3022/3023;
(n) the heavy chain and/or the light chain of antibody 3024/3025;
(o) the heavy chain and/or the light chain of antibody 3026/3027;
(p) the heavy chain and/or the light chain of antibody 3028/3029;
(q) the heavy chain and/or the light chain of antibody 3030/3031;
(r) the heavy chain and/or the light chain of antibody 3032/3033;
(s) the heavy chain and/or the light chain of antibody 3034/3035; or
(t) the heavy chain and/or the light chain of antibody 3036/3037.

### Claim 23

A polypeptide according to any of the preceding claims wherein binding domain B1 comprises the light chain variable region and the heavy chain variable region of antibody 1200/1201 (SEQ ID NO: 19 and/or SEQ ID NO: 17), or a variant which has more than 60%, or more than 70%, e.g. 75 or 80%, preferably more than 85%, e.g. more than 90 or 95% amino acid identity to SEQ ID NO: 19 and/or SEQ ID NO: 17).

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A polypeptide according to any one of claims 1 to 22 wherein binding domain B1 comprises the light chain variable region and the heavy chain variable region of antibody 1618/1619 (SEQ ID NO: 35 and/or SEQ ID NO: 33), ora variant which has more than 60%, or more than 70%, e.g. 75 or 80%, preferably more than 85%, e.g. more than 90 or 95% amino acid identity to SEQ ID NO: 35 and/or SEQ ID NO: 33).

### Claim 25

A polypeptide according to any of the preceding claims wherein binding domain B2 binds to a tumour cell-associated antigen selected from the group consisting of:
(a) products of mutated oncogenes and tumour suppressor genes;
(b) overexpressed or aberrantly expressed cellular proteins;
(c) tumour antigens produced by oncogenic viruses;
(d) oncofetal antigens;
(e) altered cell surface glycolipids and glycoproteins;
(f) cell type-specific differentiation antigens;
(g) hypoxia-induced antigens;
(h) tumour peptides presented by MHC class I;
(i) epithelial tumour antigens;
(j) haematological tumour-associated antigens;
(k) cancer testis antigens; and
(l) melanoma antigens.

### Claim 26

A polypeptide according to any of the preceding claims wherein the tumour cell-associated antigen is selected from the group consisting of 5T4, CD20, CD19, MUC-1, carcinoembryonic antigen (CEA), CA-125, C017-1A, EpCAM, HER2, EGFR, HER3, GD2, Podocalyxin, TROP-2, DLK-1, Ox1R, Nectin-4, FAP, EphA2, EphA3, mesothelin, E-cadherin, CD24 and VEGFR.

### Claim 27

A polypeptide according to any of the preceding claims wherein the tumour cell-associated antigen is an oncofetal antigen.

### Claim 28

A polypeptide according to any of the preceding claims wherein the tumour cell-associated antigen is 5T4.

### Claim 29

A polypeptide according to any of the preceding claims wherein the tumour cell is a solid tumour cell.

### Claim 30 (depends on 29)

A polypeptide according to claim 29 wherein the solid tumour is selected from the groups consisting of renal cell carcinoma, colorectal cancer, lung cancer, prostate cancer, breast cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, lymphomas, ovarian cancer, pancreatic cancer and sarcomas.

### Claim 31

A polypeptide according to any of the preceding claims wherein binding domain B2 binds to the tumour cell-associated antigen with a KD of less than 10×10−9M, for example less than 4×10−9M or less than 1.2×10−9M.

### Claim 32

A polypeptide according to any of the preceding claims wherein binding domain B2 comprises:
(a) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1206/1207 (SEQ ID NOs: 54, 55 and 56 and/or SEQ ID NOs: 45, 47 and 50);
(b) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1208/1135 (SEQ ID NOs: 54, 55 and 57 and/or SEQ ID NOs: 46, 48 and 51);
(c) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1210/1211 (SEQ ID NOs: 54, 55 and 58 and/or SEQ ID NOs: 46, 48 and 52);
(d) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 1212/1213 (SEQ ID NOs: 54, 55 and 59 and/or SEQ ID NOs: 46, 49 and 53);
(e) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 2992/2993 (SEQ ID NOs: 144, 48 and 52 and/or SEQ ID NOs: 145, 55 and 58);
(f) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 2994/2995 (SEQ ID NOs: 146, 147 and 52 and/or SEQ ID NOs: 145, 55 and 58);
(g) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 2996/2997 (SEQ ID NOs: 146, 48 and 52 and/or SEQ ID NOs: 148, 55 and 58);
(h) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 2998/2999 (SEQ ID NOs: 146, 48 and 52 and/or SEQ ID NOs: 149, 55 and 58);
(i) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3000/3001 (SEQ ID NOs: 150, 48 and 52 and/or SEQ ID NOs: 148, 151 and 58);
(j) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3002/3003 (SEQ ID NOs: 152, 48 and 52 and/or SEQ ID NOs: 145, 55 and 58);
(k) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3004/3005 (SEQ ID NOs: 146, 48 and 52 and/or SEQ ID NOs: 153, 55 and 58);
(l) the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3006/3007 (SEQ ID NOs: 144, 48 and 52 and/or SEQ ID NOs: 154, 155 and 58); or
(m)the three CDRs of the heavy chain and/or the three CDRs of the light chain of antibody 3008/3009 (SEQ ID NOs: 146, 48 and 52 and/or SEQ ID NOs: 154, 55 and 58).

### Claim 33

A polypeptide according to any of the preceding claims wherein binding domain B2 comprises:
(a) the heavy chain variable region and/or the light chain variable region of antibody 1206/1207 (SEQ ID NO: 3 and/or SEQ ID NO: 1);
(b) the heavy chain variable region and/or the light chain variable region of antibody 1208/1135 (SEQ ID NO: 7 and/or SEQ ID NO: 5);
(c) the heavy chain variable region and/or the light chain variable region of antibody 1210/1211 (SEQ ID NO: 11 and/or SEQ ID NO: 9);
(d) the heavy chain variable region and/or the light chain variable region of antibody 1212/1213 (SEQ ID NO: 15 and/or SEQ ID NO: 13);
(e) the heavy chain variable region and/or the light chain variable region of antibody 2992/2993 (SEQ ID NO: 96 and/or SEQ ID NO: 97);
(f) the heavy chain variable region and/or the light chain variable region of antibody 2994/2995 (SEQ ID NO: 98 and/or SEQ ID NO: 99);
(g) the heavy chain variable region and/or the light chain variable region of antibody 2996/2997 (SEQ ID NO: 100 and/or SEQ ID NO: 101);
(h) the heavy chain variable region and/or the light chain variable region of antibody 2998/2999 (SEQ ID NO: 102 and/or SEQ ID NO: 103);
(i) the heavy chain variable region and/or the light chain variable region of antibody 3000/3001 (SEQ ID NO: 104 and/or SEQ ID NO: 105);
(j) the heavy chain variable region and/or the light chain variable region of antibody 3002/3003 (SEQ ID NO: 106 and/or SEQ ID NO: 107);
(k) the heavy chain variable region and/or the light chain variable region of antibody 3004/3005 (SEQ ID NO: 108 and/or SEQ ID NO: 109);
(l) the heavy chain variable region and/or the light chain variable region of antibody 3006/3007 (SEQ ID NO: 110 and/or SEQ ID NO: 111); or
(m)the heavy chain variable region and/or the light chain variable region of antibody 3008/3009 (SEQ ID NO: 112 and/or SEQ ID NO: 113).

### Claim 34

A polypeptide according to any of the preceding claims wherein binding domain B2 comprises:
(a) the heavy chain and/or the light chain of antibody 1206/1207;
(b) the heavy chain and/or the light chain of antibody 1208/1135;
(c) the heavy chain and/or the light chain of antibody 1210/1211;
(d) the heavy chain and/or the light chain of antibody 1212/1213;
(e) the heavy chain and/or the light chain of antibody 2992/2993;
(f) the heavy chain and/or the light chain of antibody 2994/2995;
(g) the heavy chain and/or the light chain of antibody 2996/2993;
(h) the heavy chain and/or the light chain of antibody 2998/2999;
(i) the heavy chain and/or the light chain of antibody 3000/3001;
(j) the heavy chain and/or the light chain of antibody 3002/3003;
(k) the heavy chain and/or the light chain of antibody 3004/3005;
(l) the heavy chain and/or the light chain of antibody 3006/3007; or
(m) the heavy chain and/or the light chain of antibody 3008/3009.

### Claim 35

A polypeptide according to any of the preceding claims wherein binding domain B2 comprises the light chain variable region and the heavy chain variable region of antibody 1208/1135 (SEQ ID NO: 7 and SEQ ID NO: 5), or a variant which has more than 60%, or more than 70%, e.g. 75 or 80%, preferably more than 85%, e.g. more than 90 or 95% amino acid identity to SEQ ID NO: 7 and/or SEQ ID NO: 5).

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A polypeptide according to any one of claims 1 to 34 wherein binding domain B2 comprises the light chain variable region and the heavy chain variable region of antibody 1210/1211 (SEQ ID NO: 11 and SEQ ID NO: 9), or a variant which has more than 60%, or more than 70%, e.g. 75 or 80%, preferably more than 85%, e.g. more than 90 or 95% amino acid identity to SEQ ID NO: 11 and/or SEQ ID NO: 9).

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A polypeptide according to any one of claims 1 to 34 wherein binding domain B2 comprises the light chain variable region and the heavy chain variable region of antibody 2992/2993 (SEQ ID NO: 96 and SEQ ID NO: 97), or a variant which has more than 60%, or more than 70%, e.g. 75 or 80%, preferably more than 85%, e.g. more than 90 or 95% amino acid identity to SEQ ID NO: 96 and/or SEQ ID NO: 97).

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

A polypeptide according to any one of claims 1 to 34 wherein binding domain B2 comprises the light chain variable region and the heavy chain variable region of antibody 2994/2995 (SEQ ID NO: 98 and SEQ ID NO: 99), or a variant which has more than 60%, or more than 70%, e.g. 75 or 80%, preferably more than 85%, e.g. more than 90 or 95% amino acid identity to SEQ ID NO: 98 and/or SEQ ID NO: 99).

### Claim 39

A polypeptide according to any one of the preceding claims wherein binding domain B1 is an IgG and binding domain B2 is an scFv.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A polypeptide according to any one of claims 1 to 38 wherein binding domain B1 is an scFv and binding domain B2 is an IgG.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

A polypeptide according to any one of claims 1 to 38 wherein binding domain B1 is an scFv and binding domain B2 is an scFv (e.g. in an scFv2-Fc format).

### Claim 42

A polypeptide according to any one of the preceding claims wherein:
(a) B1 comprises the three CDRs of the light chain and/or the three CDRs of the heavy chain of antibody 1200/1201 (SEQ ID NOs: 54, 55 and 79 and/or SEQ ID NOs: 46, 65 and 72) and B2 comprises the three CDRs of the light chain and/or the three CDRs of the heavy chain of antibody 1208/1135 (SEQ ID NOs: 54, 55 and 57 and/or SEQ ID NOs: 46, 48 and 51);
(b) B1 comprises the three CDRs of the light chain and/or the three CDRs of the heavy chain of antibody 1200/1201 (SEQ ID NOs: 54, 55 and 79 and/or SEQ ID NOs: 46, 65 and 72) and B2 comprises the three CDRs of the light chain and/or the three CDRs of the heavy chain of antibody 1210/1211 (SEQ ID NOs: 54, 55 and 58 and/or SEQ ID NOs: 46, 48 and 52);
(c) B1 comprises the three CDRs of the light chain and/or the three CDRs of the heavy chain of antibody 1618/1619 (SEQ ID NOs: 54, 55 and 83 and/or SEQ ID NOs: 62, 69 and 76) and B2 comprises the three CDRs of the light chain and/or the three CDRs of the heavy chain of antibody 1208/1135 (SEQ ID NOs: 54, 55 and 57 and/or SEQ ID NOs: 46, 48 and 51); or
(d) B1 comprises the three CDRs of the light chain and/or the three CDRs of the heavy chain of antibody 1618/1619 (SEQ ID NOs: 54, 55 and 83 and/or SEQ ID NOs: 62, 69 and 76) and B2 comprises the three CDRs of the light chain and/or the three CDRs of the heavy chain of antibody 1210/1211 (SEQ ID NOs: 54, 55 and 58 and/or SEQ ID NOs: 46, 48 and 52).

### Claim 43

A polypeptide according to any one of the preceding claims wherein:
(a) B1 comprises the light chain variable region and/or the heavy chain variable region of antibody 1200/1201 (SEQ ID NO: 19 and/or SEQ ID NO: 17) and B2 comprises the light chain variable region and/or the heavy chain variable region of antibody 1208/1135 (SEQ ID NO: 7 and/or SEQ ID NO: 5);
(b) B1 comprises the light chain variable region and/or the heavy chain variable region of antibody 1200/1201 (SEQ ID NO: 19 and/or SEQ ID NO: 17) and B2 comprises the light chain variable region and/or the heavy chain variable region of antibody 1210/1211 (SEQ ID NO: 11 and/or SEQ ID NO: 9);
(c) B1 comprises the light chain variable region and/or the heavy chain variable region of antibody 1618/1619 (SEQ ID NO: 35 and/or SEQ ID NO: 33) and B2 comprises the light chain variable region and/or the heavy chain variable region of antibody 1208/1135 (SEQ ID NO: 7 and/or SEQ ID NO: 5); or
(d) B1 comprises the light chain variable region and/or the heavy chain variable region of antibody 1618/1619 (SEQ ID NO: 35 and/or SEQ ID NO: 33) and B2 comprises the light chain variable region and/or the heavy chain variable region of antibody 1210/1211 (SEQ ID NO: 11 and/or SEQ ID NO: 9); or
(e) B1 and/or B2 comprise variants of said light chain variable regions and/or said heavy chain variable regions having at least 90% sequence identity thereto.

### Claim 44

A polypeptide according to any one of the preceding claims wherein B1 comprises the light chain variable region and/or the heavy chain variable region of antibody 1200/1201 (SEQ ID NO: 19 and/or SEQ ID NO: 17) and B2 comprises the light chain variable region and/or the heavy chain variable region of antibody 1210/1211 (SEQ ID NO: 11 and/or SEQ ID NO: 9), or variants of said light chain variable regions and/or said heavy chain variable regions (for example, having at least 90% sequence identity thereto), or vice versa.

### Claim 45

A polypeptide according to any one of the preceding claims wherein B1 comprises the light chain variable region and/or the heavy chain variable region of antibody 1618/1619 (SEQ ID NO: 35 and/or SEQ ID NO: 33) and B2 comprises the light chain variable region and/or the heavy chain variable region of antibody 1210/1211 (SEQ ID NO: 11 and/or SEQ ID NO: 9), or variants of said light chain variable regions and/or said heavy chain variable regions (for example, having at least 90% sequence identity thereto), or vice versa.

### Claim 46

A polypeptide according to any one of the preceding claims comprising a heavy chain constant region having an amino acid sequence of SEQ ID NO:94 or 96 and/or a light chain constant region having an amino acid sequence of SEQ ID NO:95.

### Claim 47

A polypeptide according to any one of the preceding claims wherein the polypeptide comprises at least one of the following:
(a) an Fc region comprising ‘LALA’ mutations;
(b) an scFv comprising mutations in the heavy and light chain variable regions to cysteine residues capable of forming a disulphide bridge; and/or
(c) an scFv comprising mutation in the heavy chain variable region to create one or more N-glycosylation sites.

### Claim 48

A polypeptide according to any one of the preceding claims comprising
(a) a binding domain (B1) comprising a heavy chain variable region of any of SEQ ID NOs: 17, 21, 27, 29, 33, 37, 41, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136 or 138 and a light chain variable region of any of SEQ ID NOs: 19, 23, 25, 31, 35, 39, 43, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135 or 139;
(b) a heavy chain constant region comprising an Fc region (for example, SEQ ID NO: 94 or 96);
(c) a binding domain (B2) comprising a heavy chain variable region of any of SEQ ID NOs: 1, 5, 9, 13, 96, 98, 100, 102, 104, 106, 108, 110 or 112 and a light chain variable region of any of SEQ ID NOs: 3, 7, 11, 15, 97, 99, 101, 103, 105, 107, 109, 111 or 113; and
(d) optionally, a light chain constant region (for example SEQ ID NO:95).

### Claim 49

An isolated nucleic acid molecule encoding a bispecific polypeptide according to any one of the preceding claims, or a component polypeptide chain thereof.

### Claim 50 (depends on 49)

A nucleic acid molecule according to claim 49 wherein the molecule is a cDNA molecule.

### Claim 51 (depends on 49, 50)

A nucleic acid molecule according to claim 49 or 50 encoding an antibody heavy chain or variable region thereof.

### Claim 52 (depends on 49, 50, 51)

A nucleic acid molecule according to any one of claims 49 to 51 encoding an antibody light chain or variable region thereof.

### Claim 53 (depends on 49, 50, 51, 52)

A vector comprising a nucleic acid molecule according to any one of claims 49 to 52.

### Claim 54 (depends on 53)

A vector according to claim 53 wherein the vector is an expression vector.

### Claim 55 (depends on 49, 50, 51, 52, 53, 54)

A recombinant host cell comprising a nucleic acid molecule according to any one of claims 49 to 52 or a vector according to claim 53 or 54.

### Claim 56 (depends on 55)

A host cell according to claim 55 wherein the host cell is a bacterial cell.

### Claim 57 (depends on 55)

A host cell according to claim 55 wherein the host cell is a mammalian cell.

### Claim 58 (depends on 55)

A host cell according to claim 55 wherein the host cell is a human cell.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 55, 56, 57, 58)

A method for producing bispecific polypeptide according to any one of the claims 1 to 48, the method comprising culturing a host cell as defined in any of claims 55 to 58 under conditions which permit expression of the bispecific polypeptide or component polypeptide chain thereof.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A pharmaceutical composition comprising an effective amount of bispecific polypeptide according to any one of the claims 1 to 48 and a pharmaceutically-acceptable diluent, carrier or excipient.

### Claim 61 (depends on 60)

A pharmaceutical composition according to claim 60 adapted for parenteral delivery.

### Claim 62 (depends on 60)

A pharmaceutical composition according to claim 60 adapted for intravenous delivery.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A bispecific polypeptide according to any one of the claims 1 to 48 for use in medicine.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A bispecific polypeptide according to any one of the claims 1 to 48 for use in treating or preventing a neoplastic disorder in a subject.

### Claim 65 (depends on 64)

A polypeptide for use according to claim 64 wherein the neoplastic disorder is associated with the formation of solid tumours within the subject's body.

### Claim 66 (depends on 65)

A polypeptide for use according to claim 65 wherein the solid tumour is selected from the group consisting of prostate cancer, breast cancer, lung cancer, colorectal cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, lymphomas, ovarian cancer, pancreatic cancer and sarcomas.

### Claim 67 (depends on 66)

A polypeptide for use according to claim 66 wherein the solid tumour is selected from the groups consisting of renal cell carcinoma, colorectal cancer, lung cancer, prostate cancer and breast cancer.

### Claim 68 (depends on 64, 65, 66, 67)

A polypeptide for use according to any one of claims 64 to 67 wherein the polypeptide is for use in combination with one or more additional therapeutic agents.

### Claim 69 (depends on 68)

A polypeptide for use according to claim 68 wherein the one or more additional therapeutic agents is/are an immunotherapeutic agent that binds a target selected from the group consisting of PD-1/PD-1L, CTLA-4, OX40, CD40, GITR, LAG3, TIM3, CD27 and KIR.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

Use of a bispecific polypeptide according to any one of the claims 1 to 46 in the preparation of a medicament for treating or preventing a neoplastic disorder in a subject.

### Claim 71 (depends on 70)

A use according to claim 70 wherein the neoplastic disorder is associated with the formation of solid tumours within the subject's body.

### Claim 72 (depends on 71)

A use according to claim 71 wherein the solid tumour is selected from the group consisting of prostate cancer, breast cancer, lung cancer, colorectal cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, lymphomas, ovarian cancer, pancreatic cancer and sarcomas.

### Claim 73 (depends on 72)

A use according to claim 72 wherein the solid tumour is selected from the groups consisting of renal cell carcinoma, colorectal cancer, lung cancer, prostate cancer and breast cancer.

### Claim 74 (depends on 70, 71, 72, 73)

A use according to any one of claims 70 to 73 wherein the polypeptide is for use in combination with one or more additional therapeutic agents.

### Claim 75 (depends on 74)

A polypeptide for use according to claim 74 wherein the one or more additional therapeutic agents is/are an immunotherapeutic agent that binds a target selected from the group consisting of PD-1/PD-1L, CTLA-4, OX40, CD40, GITR, LAG3, TIM3, CD27 and KIR.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A method for the treatment or diagnosis of a neoplastic disorder in a subject, comprising the step of administering to the subject an effective amount of a bispecific polypeptide according to any one of the claims 1 to 48.

### Claim 77 (depends on 76)

A method according to claim 76 wherein the neoplastic disorder is associated with the formation of solid tumours within the subject's body.

### Claim 78 (depends on 77)

A method according to claim 77 wherein the solid tumour is selected from the group consisting of prostate cancer, breast cancer, lung cancer, colorectal cancer, melanomas, bladder cancer, brain/CNS cancer, cervical cancer, oesophageal cancer, gastric cancer, head/neck cancer, kidney cancer, liver cancer, lymphomas, ovarian cancer, pancreatic cancer and sarcomas.

### Claim 79 (depends on 78)

A method according to claim 78 wherein the solid tumour is selected from the groups consisting of renal cell carcinoma, colorectal cancer, lung cancer, prostate cancer and breast cancer.

### Claim 80 (depends on 76, 77, 78, 79)

A method according to any one of claims 76 to 79 wherein the subject is human.

### Claim 81 (depends on 76, 77, 78, 79, 80)

A method according to any one of claims 76 to 80 wherein the method comprises administering the bispecific antibody systemically.

### Claim 82 (depends on 76, 77, 78, 79, 80, 81)

A method according to any one of claims 76 to 81 further comprising administering to the subject one or more additional therapeutic agents.

### Claim 83 (depends on 76, 77, 78, 79, 80, 81, 82)

A method according to any one of claims 76 to 82 wherein the one or more additional therapeutic agents is/are an immunotherapeutic agent that binds a target selected from the group consisting of PD-1/PD-1L, CTLA-4, OX40, CD40, GITR, LAG3, TIM3, CD27 and KIR.

### Claim 84

A bispecific polypeptide substantially as described herein with reference to the description and figures.

### Claim 85

A polynucleotide substantially as described herein with reference to the description and figures.

### Claim 86

A pharmaceutical composition substantially as described herein with reference to the description and figures.

### Claim 87

Use of a bispecific polypeptide substantially as described herein with reference to the description and figures.

### Claim 88

A method of treatment substantially as described herein with reference to the description and figures.
